<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="149574">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01766388</url>
  </required_header>
  <id_info>
    <org_study_id>1005</org_study_id>
    <nct_id>NCT01766388</nct_id>
  </id_info>
  <brief_title>Mifepristone and Misoprostol for Mid-trimester Termination of Pregnancy in Armenia</brief_title>
  <official_title>Mifepristone and Misoprostol for Mid-trimester Termination of Pregnancy (13-22 Weeks LMP) in Armenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gynuity Health Projects</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gynuity Health Projects</source>
  <oversight_info>
    <authority>Armenia: Ministry of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary goal of this study is to examine the efficacy and feasibility of a mifepristone
      combined with misoprostol medical abortion regimen in terminating pregnancies 13-22 weeks in
      Armenia.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2012</start_date>
  <primary_completion_date type="Anticipated">November 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case-Only, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Rate of successful abortion</measure>
    <time_frame>Every 3 hours after induction with misoprostol commences, up to 30 hours after the first dose</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Induction to fetal expulsion interval</measure>
    <time_frame>Time from administration of first misoprostol dose to expulsion of the fetus, up to 30 hours after the first dose</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Induction to fetal and placental expulsion interval</measure>
    <time_frame>Time from administration of first misoprostol dose to expulsion of the fetus and placenta, up to 30 hours after the first dose</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total dose of misoprostol</measure>
    <time_frame>At the time of fetal and placental expulsion, up to 30 hours after the first dose</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Women's satisfaction with the method</measure>
    <time_frame>At discharge, up to 5 days after enrollment</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side effects</measure>
    <time_frame>Every 3 hours, starting from the first dose of misoprostol, up to fetal and placental expulsion or 30 hours after the first dose, whichever occurs first</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Women's acceptability of the side effects, buccal administration of misoprostol, and duration of procedure</measure>
    <time_frame>At discharge, up to 5 days after enrollment</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Providers' acceptability of the method</measure>
    <time_frame>After all study procedures complete, at close out, up to 1.5 years after study enrollment commences</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications including heavy bleeding, uterine rupture, or infection requiring additional treatment</measure>
    <time_frame>Every 3 hours, starting from the first dose of misoprostol, up to fetal and placental expulsion, or 30 hours after the first dose, whichever occurs first</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Women, Pregnant</condition>
  <condition>13-22 Weeks Gestation</condition>
  <arm_group>
    <arm_group_label>Pregnant women</arm_group_label>
    <description>Pregnant women of 13-22 weeks gestation</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        All women presenting to a study clinic in Yerevan, Armenia for voluntary termination of
        intrauterine pregnancy with gestational ages of 13-22 weeks
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria, aside from being in good general health and have a pregnancy of 13-22
        weeks gestation:

          1. Meet legal criteria to obtain abortion

          2. Present with closed cervical os and no vaginal bleeding

          3. Live fetus at time of presentation for service

          4. Be willing to undergo a surgical completion if necessary

          5. Have no contraindications to study procedures, according to provider

          6. Be willing and able to consent to procedure, either by reading consent document or by
             having consent document read to her

          7. Be willing to follow study procedures

        Exclusion criteria:

          1. Known previous transmural uterine incision

          2. Known allergy to mifepristone or misoprostol/prostaglandin or other contraindications
             to the use of mifepristone or misoprostol

          3. Parity greater than 5.

          4. Any contraindications to vaginal delivery, including placenta previa

          5. Presentation in active labor (defined as moderate to severe contractions every 10
             minutes or less)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ruzanna Abrahamyan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Republican Institute of Reproductive Health, Perinatology, Obstetrics and Gynecology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gayane Abrahamyan, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>State Medical University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Beverly Winikoff, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gynuity Health Projects</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Republican Institute of Reproductive Health, Perinatology, Obstetrics and Gynecology</name>
      <address>
        <city>Yerevan</city>
        <zip>0078</zip>
        <country>Armenia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruzanna Abrhamyan, MD</last_name>
      <phone>(+374 91) 40 57 18</phone>
      <email>r_abrahamyan@mail.ru</email>
    </contact>
    <investigator>
      <last_name>Ruzanna Abrahamyan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>State Medical University</name>
      <address>
        <city>Yerevan</city>
        <zip>0025</zip>
        <country>Armenia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gayane Avagyan, MD, PhD</last_name>
      <phone>(+374 91) 45 81 35</phone>
      <email>gavagyan@moh.am</email>
    </contact>
    <investigator>
      <last_name>Gayane Avagyan, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Armenia</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <lastchanged_date>January 9, 2013</lastchanged_date>
  <firstreceived_date>December 6, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Mifepristone</mesh_term>
    <mesh_term>Misoprostol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
